

BAB V

KESIMPULAN DAN SARAN

A. Kesimpulan

Berdasarkan dari penelitian yang telah dilakukan dapat disimpulkan sebagai berikut :

Pertama, piroxicam dapat dibuat sediaan gel piroxicam yang memenuhi mutu fisik dan stabilitas yang baik.

Kedua, sediaan gel piroxicam dengan variasi *gelling agent* dapat digunakan untuk penyembuhan luka sayat pada penderita diabetes.

Ketiga, konsentrasi *gelling agent* dengan perbandingan HPMC 0,5%: Carbopol 1,5% (formula 2) merupakan konsentrasi efektif untuk penyembuhan luka.

B. Saran

Pertama, perlu dilakukan penelitian lebih lanjut ke tingkat histologi kulit untuk mengetahui aktivitas penyembuhan luka.

Kedua, untuk peneliti selanjutnya diharapkan untuk pembuatan luka sayat pada hewan uji digunakan biopsy punch dengan kedalaman 6 mm.

Ketiga, perlu dilakukan pengukuran kadar *matrix metalloproteinase* 9

DAFTAR PUSTAKA

- 4h-Ontario. 2009. 4-H Rabbit Manual. Quelp, on NIH 6j2. Canada: 4-H Ontario
- Abd-Allah FI et al. 2011. Evaluation of the anti-inflammatory and analgesic effect of piroxicamloaded microemulsion in topical formulations. *International Journal of Pharmacy and Pharmaceutical Sciences* 3(2) hlm 66-70.
- [ADA] American Diabetes Association. 2010. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. (suppl.1).
- [ADA] American Diabetes Association. 2013. Standards of medical care in diabetes- *Diabetes Care*. (suppl.1).
- [ADA] American Diabetes Association. 2015. Standards of medical care in diabetes. *Diabetes Care*. (suppl.1). S1-S2.
- Allen LV, Nicholas GP, Howard CA. 2011. *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems 9th Ed*. China: Lippicott Williams & Wilkins, a Wolters Kluwer business.
- Almekinders LC, Gilbert JA. 1986. Biomechanical properties of muscle after experimental muscle strains and the role of nonsteroidal antinflammatory medication. *Trans Orthop Res Soc* (11). Hlm 224-229.
- Aly UF. 2012. Preparation and evaluation of novel topical gel preparation for wound healing in diabetic. *International Journal of Pharmacy and Pharmaceutical Siences* 4(11).
- Ansel HC. 1989. *Penghantar Bentuk Sediaan Farmasi*. Edisi Keempat. Jakarta: UI Press.
- Ansel HC. 2008. *Pengantar Bentuk Sediaan Farmasi*. Jakarta: UI Press.
- Arikumalasari JI. 2013. Optimasi HPMC sebagai gelling agent dalam formula gel ekstrak kulit buah manggis(*Garcinia mangostana L*). *Jurnal Farmasi Udayana*. 2(3)
- Arisanty IP. 2013. *Panduan Praktis Pemilihan Balutan Luka Kronik Edisi 2*. Jakarta: Penerbit Mitra Wacana Medika. Hlm 1
- Arisanty IP. 2014. *Manajemen Perawatan Luka: Konsep Dasar*. Jakarta: EGC
- Astuti DP, Husni P, Hartono K. 2017. Formulasi dan uji stabilitas fisik sediaan gel antiseptik tangan minyak atsiri bunga lavender (*Lavandula angustifolia Miller*). *Jurnal Farmaka* Vol 15 (1).

- Azkiya, Zulfa, Herda, A & Tyas, SN. 2017. Evaluasi sifat fisik krim ekstrak jahe merah (*Zingiber officinale* Rosc. var. *rubrum*) sebagai anti nyeri. *Journal of Current Pharmaceutical Sciences*, 1 (1): 12-18.
- Banks R. 1989. Diabetes melitus. USAMRID Seminar Series
- Barasa, M. 2016. Formulasi gel antioksidan ekstrak kulit buah manggis (*Garcinia mangostana* L) dalam berbagai variasi konsentrasi CMC-Na dan gliserin. Fakultas Farmasi Universitas Sanata Dharma Yogyakarta
- Baroroh, Dwi. 2011. Konsep luka. Fakultas Ilmu Kesehatan Universitas Muhammadiyah Malang. Hlm 2
- Baxter, C. 1990. The normal healing process. In: *New Directions in Wound Healing*. NJ: E.R. Squibb & Sons, Inc. Princeton.
- Berman, Audrey. 2009. *Buku Ajar Praktik Keperawatan Klinis Edisi Kelima*. Jakarta. EGC: Penerbit Buku Kedokteran
- Brander, J.M., et al. 2008. Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after translocation into an ex vivo wound-healing model. *Diabetes Care* 31(1): January 2008
- Buchan, B., Kay, G., Heneghan, A., Matthews, K. H., & Cairns, D. 2010. Gel formulations for treatment of the ophthalmic complications in cystinosis. *International Journal of Pharmaceutics* 392(1), 192-197
- Corwin, E.J. 2009. *Buku Saku Patofisiologi*. Subekti NB, penerjemah; Yudha EK, Wahyuningsih E, Yulianti D, Karyuni PE, editor. Jakarta: EGC. Terjemahan dari: *Handbook of Pathophysiology*
- [Depkes RI] Departemen Kesehatan Republik Indonesia. 1979. Farmakope Indonesia. Edisi III. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik Direktorat Jendral Bina Kefarmasian dan Alat kesehatan Departemen Kesehatan Republik Indonesia.
- [Depkes RI] Departemen Kesehatan Republik Indonesia. 1980. Kodeks Kosmetika Indonesia. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik Direktorat Jendral Bina Kefarmasian dan Alat kesehatan Departemen Kesehatan Republik Indonesia.
- [Depkes RI] Departemen Kesehatan Republik Indonesia. 2005. Pharmaceutical Care Untuk penyakit Diabetes melitus. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik Direktorat Jendral Bina Kefarmasian dan Alat kesehatan Departemen Kesehatan Republik Indonesia.

- [Depkes RI] Departemen Kesehatan Republik Indonesia. 2006. *Pharmaceutical Care Untuk Penyakit Diabetes Mellitus*. Jakarta: Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan Republik Indonesia.
- Ditjen Bina Farmasi dan Alkes. 2005. *Pharmaceutical Care untuk Penyakit Diabetes Mellitus*. Jakarta: Departemen Kesehatan RI.
- Ditjen POM. 1995. *Farmacope Indonesia Edisi IV*. Jakarta: Departemen Kesehatan RI.
- Dipiro JT, Talbert RL, and Yee GC. 2005. *Pharmacotherapy: a Pathophysiologic Approach, 4th Ed.*, 1334, Appleton & Lange, USA.
- Dipiro JT, Wells BG, Schwinghammer TL, and Hamilton CW. 2006. *Pharmacotherapy handbook, 6th Edition*, New York: Appleton and Lange.
- Falanga, V. 2004. The Chronic Wound: Impaired healing and solutions in the context of wound bed preparation. *Blood Cells, Molecules and Diseases*. 32(1) hlm 88-94
- Hamed S et al. 2014. A novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus. *Wound Repair and Regeneration*. 22 (1). hlm 23-33
- Herdiana Y. 2007. Formulasi gel undesilenil fenilananin dalam aktivitas sebagai pencerah kulit. [Karya ilmiah]. Fakultas Farmasi Unpad Jatnagor.
- Hunter JAA, Savin JA, Dahl MV. 2002. *Clinical Dermatology Thrid Edition*. United Kingdom: Blackwell Publishing.
- Hurria. 2014. Formulasi, uji stabilitas fisik, dan uji aktifitas sediaan gel hand sanitizer dari air perasan jeruk nipis (*Citrus aurantifolia Swingle*) berbasis karbomer. *Jurnal Farmasi FIK UINAM*, 2 (1): 28-33.
- Hustamin, Rudy. 2006. *Panduan Memelihara Kelinci Hias*. Agro Media Pustaka. Jakarta
- [IDF]. International Diabetes Federation. 2015. *Diabetes Atlas 7th Edition*: IDF.
- Ikatan Apoteker Indonesia. 2014. *ISO informasi Spesialite Obat Indonesia*. Volume 49 2014 s/d 2015. Jakarta: PT ISFI Penerbitan
- Jufri, M., Anwar, E., Utami ,P.M., 2006. Uji stabilitas sediaan mikroemulsi menggunakan hidrolisat pati (DE 35-40) sebagai stabilizer. *Majalah Ilmu Kefarmasian*, 3(1):8-21.
- Kartadisastra HR. 1997. *Penyelidikan dan Pengolahan Pakan Ternak Ruminasnsia*. Kanisius: Yogyakarta

- Kartika B., Guritno AD., dan Ismoyowati. 1997. *Petunjuk Evaluasi Prooduk Industri Hasil Pertanian*. PAU Pangan dan Gizi UGM. Yogyakarta.
- Keeble E. 2001. Endocrine disease in small mammals: in practice. *Britsh Veterninary Recordin Conjunction with The Veterinary Record* (23) hlm 570-586.
- Kementrian Kesehatan Republik Indonesia. 2014. *Farmakope Indonesia Edisi V*. Kementrian Kesehatan RI. Jakarta
- Koda Kimble M.A.Young L.Y. Kradjan W.A. Guglielmo B.J. 2009. *General Care. in: Applied Theurapeutics: The Clinical Use of Drugs 10th Edition*. Lippincott Williams and Wilkin. Philadelphia
- Lachman, L. et al. 1994. *Teori Dan Praktek Farmasi Industri*. Terjemahan Siti Suyatmi. Edisi Ketiga. Jakarta: Penerbit Universitas Indonesia.
- Lestari, T., 2002. Hand and body lotion: pengaruh penambahan nipagin,nipasol dan campuran keduanya terhadap stabilitas fisika danefektifitasnya sebagai anti jamur. [Skripsi]. Yogyakarta: Fakultas Farmasi, Universitas Gajah Mada.
- Lobmann, R., et al. 2002. Expression of matrix-metalloproteinase and their inhibitor in the wounds of diabetic and non-diabetic patients. *Diabetologia* 45(7): 1011-1016.
- Madinur CRJ, Tubachi P, Godhi AS. 2018. A comparative study of the effect of piroxicam versus diclofenac on wound healing in clean abdominal wounds. *International Surgery Journal* 5(3): 1041-1045
- Mazumder MK, Bhattacharya P, Borah A. 2014. Inhibition of matrix metalloproteinase-2 and 9 by piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis. *Medical Hypothesis* 83(6) hlm 697-701.
- Mescher AL. 2010. *Junqueira's Basic Histology Text & Atlas*. New York: McGraw Hill Medical.
- McLennan SV, et al. 2008. The anti-inflannatory agent propolis improves wound healing in a rodent model of experimental diabetes. *Wound Rep Reg* 16 hlm 706–713
- Misal G, Gouri D, Vijay G. 2012. Formulaton and evaluation of herbal gel. *Indian Journal of Natural Product and Resources* 3(4): 501-505
- Moenadjat Y.2001. *Luka Bakar Pengetahuan Klinis Praktis*. Jakarta: BP-FK-UI. Hlm 1-91
- Morris, P. J., Malt, R. A. 1990. *Oxford Textbook of Surgery*. Oxford University Press. New York.

- Mukhlisah N. R. I, Sugihartini N, Yuwono T. 2016. Daya Iritasi dan Sifat Fisik Sediaan Salep Minyak Atsiri Bunga Cengkeh (*Syzigium aromaticum*) Pada Basis Hidrokarbon. *Majalah Farmasetik* vol 12 No 1.
- Naibaho, Olivia H., Paulina V.Y., Yamlean, Weny Wiyono. 2013. Pengaruh basis salep terhadap formulasi sediaan salep ekstrak daun kemangi (*Ocimum Sanctum L.*) pada kulit punggung kelinci yang dibuat infeksi *Staphylococcus aureus*. *Jurnal Ilmiah Farmasi UNSRAT* 2(2) ISSN 2302-2493.
- Ndraha S. 2014. Diabetes Mellitus Tipe 2 dan Tata Laksana Terkini. Departemen Penyakit Dalam. Jakarta: FK Universitas Krida Wacana
- Perkumpulan Endokrinologi Indonesia (PERKENI). 2011. *Konsensus Pencegahan dan Pengendalian Diabetes Melitus Tipe 2 di Indonesia*. Jakarta: PB PERKENI.
- Powers, Alvin C., 2012. *Diabetes Mellitus*. Dalam : Longo, D.L., Fauci, A.S., Kasper, D.L., Hauser, S.L., Jameson, J.L., Loscalzo, J. Penyunting: Harrison's Principles of Internal Medicine. 18th Ed. USA : McGraw-Hill. Chapter 344.
- Powers, A.C. 2015b. *Diabetes Mellitus: Diagnosis, Classification and Pathophysiology*. Dalam: Kasper, D.L., Fauci, A.S., Longo, D.L., Loscalzo, J., Hauser, S.L., Jameson, J.L. Penyunting: Harrison's Principles of Internal Medicine Edisi ke-19. New York: McGraw-Hill Education
- Quinones, D., & Ghaly, E. S. 2008. Formulation and characterization of nystatin gel. *Puerto Rico Health Sciences Journal*, 27(1).
- Rai, N., Sarkar, M dan Raha, S. 2015. Piroxicam a traditional non-steroidal antiinflammatory drug (NSAID) causes apoptosis by ROS mediated akt activation. *Pharmacological Reports*, 67(6) hlm 1215-1233.
- Rowe RC, Sheskey PJ, dan Quinn ME. 2009. *Handbook of Pharmaceutical Excipient, Dysperse System. Volume 2. Edisi 6*. London : Pharmaceutical Press. Inc.
- Sahay BK. 2012. Infection in Diabetes Mellitus. In: RSSDI Textbook of Diabetes Mellitus. 2nd edition. Triphaty & Chandalia Publ hlm 218-220.
- Saruang V, Yamlean PV, Citraningtyas G. 2018. Pengaruh variasi basis karbopol dan HPMC pada formulasi gel ekstrak etanol daun tapak kuda (*Ipomoea pes-caprae* (L.) dan uji aktivitas antiabakteri terhadap *Staphylococcus aureus*. *Jurnal Ilmiah Farmasi* 7 (3) ISSN 2302 – 2493
- Sarwono B. 2001. *Kelinci Potong Hias*. Agro Media Pustaka. Jakarta
- Sharom N, Syaiful A, Yuliet. 2013. Formulasi krim antioksidan ekstrak etanol bawang hutan (*Eleutherine palmifolia L. Merr*). *Journal of Natural Science* 2(3): 111-122

- Sonny, J.R. 2013. Histofisiologi kulit. *Jurnal Biomedik*; 5(3).
- Sudarmadji, S., B. Haryono, Suhardi. 1984. *Prosedur Analisa untuk Bahan Makanan dan Pertanian*. Yogyakarta: Penerbit Liberty
- Suyono U. 2007. *Patofisiologis Diabetes Melitus*. Dalam Penatalaksanaan Diabetes Melitus Terpadu, Soegando, S., Soewondo, P., & Subekti, I. Pusat Diabetes dan Lipid RSUP Nasional Dr Cipto Mangunkusumo, Jakarta : FKUI.
- Szkudelski T. 2001. The mechanism of alloxan and streptozotocin action in β cells of the rat pancreas. *In: Physiology Research*. P. 536-554.
- Udegbuna RI, Agu NN. 2012. Efficiency of piroxicam on acute pain induced by full thickness excision wounds in rats. *African Journal of Pharmacy and Pharmacology* (6) 23.
- Voigt, R. 1994. *Buku Pelajaran Teknologi Farmasi*. Edisi ke-5. Yogyakarta: Gadjah Mada University Press.
- Wyatt, Jonathan. 2011. *Forensic Medicine*. New York: Oxford University Press.
- Yuriska, F.A. 2009. Efek aloksan terhadap kadar glukosa darah tikus wistar. [Skripsi]. Semarang: Fakultas Kedokteran Universitas Diponegoro.

L A M P I R A N

Lampiran 1. Surat kelayakan etik penelitian

8/13/2019

KEPK-RSDM



HEALTH RESEARCH ETHICS COMMITTEE
KOMISI ETIK PENELITIAN KESEHATAN

Dr. Moewardi General Hospital
RSUD Dr. Moewardi

ETHICAL CLEARANCE
KELAIKAN ETIK

Nomor : 983 / VIII / HREC / 2019

The Health Research Ethics Committee Dr. Moewardi
Komisi Etik Penelitian Kesehatan RSUD Dr. Moewardi

after reviewing the proposal design, herewith to certify
setelah menilai rancangan penelitian yang diusulkan, dengan ini menyatakan

That the research proposal with topic :
Bahwa usulan penelitian dengan judul

**FORMULASI DAN UJI AKTIVITAS GEL PIROXICAM DENGAN VARIASI BASIS KARBOPOL DAN HPMC UNTUK LUKA SAYAT
PENDERITA DIABETES TIPE II**

Principal investigator : Farikha Baridwan
Peneliti Utama 22164736A

Location of research : Universitas Setia Budi
Lokasi Tempat Penelitian

Is ethically approved
Dinyatakan layak etik

Issued on : 13 Agustus 2019



Chairman
Ketua

Dr. Wahyu Dwi Armoko., Sp.F
19770224-201001 1 004

rsmoewardi.com/komisi-etika/kepk/ethicalclearance/22164736A-0543

1/1

Lampiran 2. Sertifikat analisis piroxicam



FDA MAHARASHTRA

Letter No: MH/TZ/GMP/6078987
Food & Drugs Administration, KONKAN Division
OFFICE OF JOINT COMMISSIONER (K.D)
4TH FLOOR BLD, WAGLE ESTATE
Thane - 400604

CERTIFICATE No: 6078987
Issue & Valid Upto Dt: 18/12/2017 - 17/12/2018

GMP CERTIFICATE

This is to certify that **RAMDEV CHEMICALS PVT. LTD., (705361), PLOT NO.E-41, MIDC, TARAPUR, BOISAR - 401506, Dist - THANE-ZONE4** is holding valid Drugs Manufacturing License in

Form 25, Licence No. KD/442, Iss Dt: 03/05/2001, Val Dt: 31/12/2017, Ren Dt: 20/05/2013,

issued by this administration under the provision of DRUGS & COSMETICS ACT 1940 & RULES THERE UNDER. Under the said licenses the firm is permitted to manufacture and sell their products covered under the

Categories of: Bulk Drugs / API

The firm has employed competent technical persons in manufacturing and quality control departments. The said firm observes **GOOD MANUFACTURING PRACTICES (GMP)** in the manufacturing and testing of the said categories of products by and large as laid down in revised Schedule 'M' of the Drugs & Cosmetics Rules 1945.

The manufacturing plant is subject to regular inspection by the Competent Authority under The Act.

This Certificate is issued for: purpose of - (For Export Registration)

This Certificate is Valid for a period: 18/12/2017 - 17/12/2018

eSign
Digitally Sign with Aadhaar

VIRAJ TUKARAM PAUNIKAR
e-Signed on 18-12-2017 23:27
(Organic Authentication on AADHAR from UIDAI Server)
IPAV #45YF3Y29ML

Applicant:
RAMDEV CHEMICALS PVT. LTD., (705361)
PLOT NO.E-41, MIDC, TARAPUR, BOISAR - 401506
Taluka: MIDC TARAPUR BHOISAR District: THANE-ZONE4





V.T Poonikar
Licensing Authority
Food & Drugs Administration
KONKAN Division, Maharashtra State



FDA MAHARASHTRA

Fee Payment(s): DB-Id: 245444 - 31/10/2017 (Amt: 3500) Balance: 200

This License/Certificate is eSIGNED with Seeding from AADHAR via UIDAI Server. Physical Signature is NOT Required

Division	MFG ID No.	Type: GMP Certificate	CERTIFICATE No.	Issue Dt/ Validity Dt.
KONKAN (TZ4)	705361	GMP-705361-11/12/2017	6078987	18/12/2017 - 17/12/2018


RAMDEV CHEMICAL PVT. LTD.

Regd. Office & Factory :
E-41 & 129, M.I.D.C. Industrial Area, Tarapur,
Boisar, Dist: Palghar - 401-508, Maharashtra (India)
Telephone : 0091-2525-645957, +91 9320010323
E-mail : qualityunits@ramdevchem.com
Website : www.ramdevchem.com

Format No.: RCPL/QC/3076/F-01

Lic. No.: KD-442


In-House Additional Test			
08.	Melting Range	Between 198°C to 200°C	198.6°C to 199.3°C
09.	Clarity of solution	A solution of 1 gm sample in 10 ml chloroform should be clear.	A solution of 1 gm sample in 10 ml chloroform is clear.
10.	Specific Bulk Density	Between 0.25 to 0.4 gm/ml	0.308 gm/ml
11.	Particle Size By Malvern	100% Less than 15 microns	9.96 microns
12.	Assay by Potentiometric	Not less than 98.5% & not more than 101.0%, calculated on anhydrous basis.	99.770 %

Piroxicam, Batch No. PX-26/18-19 complies with USP + In-House specification for above tests.



Prepared By Name : Snehaj mhalke Designation : Q.C. officers Sign. & Date : <i>Snehaj</i> 21/08/18	Reviewed By Name : Alakhata Dandekar Designation : Q.C. officer Sign. & Date : <i>Alakhata</i> 21/08/18	Approved By Name : <i>Suresh B. Sengh</i> Designation : <i>Q.C. officer</i> Sign. & Date : <i>[Signature]</i> 21-08-18
--	---	--

Lampiran 3. Gambar sediaan gel piroxicam dan alat uji



Sediaan gel piroxicam



Alat uji daya sebar



Alat uji pH



Alat uji viskositas



Alat uji daya lekat

Lampiran 4. Hasil uji viskositas sediaan gel piroxicam

Data Uji Viskositas (dPAS)				
	F1	F2	F3	F4
Hari 1	300	340	440	500
	310	350	450	510
	300	350	450	515
Hari 7	300	375	465	515
	310	380	465	520
	310	380	460	520
Hari 14	315	390	470	525
	310	395	480	520
	315	390	470	530
Hari 21	320	400	490	530
	320	415	480	535
	315	400	480	540

Lampiran 5. Hasil statistik uji viskositas sediaan gel piroxicam

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Viskositas	48	419,7917	82,93780	300,00	540,00

One-Sample Kolmogorov-Smirnov Test

		Viskositas
N		48
Normal Parameters ^{a,b}	Mean	419,7917
	Std. Deviation	82,93780
	Absolute	,136
Most Extreme Differences	Positive	,136
	Negative	-,124
Kolmogorov-Smirnov Z		,939
Asymp. Sig. (2-tailed)		,341

Levene's Test of Equality of Error Variances^a

Dependent Variable: Viskositas

F	df1	df2	Sig.
1,429	15	32	,193

Tests of Between-Subjects Effects

Dependent Variable: Viskositas

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	322431,250 ^a	15	21495,417	793,677	,000
Intercept	8458802,083	1	8458802,083	312325,000	,000
Kelompok	313068,750	3	104356,250	3853,154	,000
Waktu	7610,417	3	2536,806	93,667	,000
Kelompok * Waktu	1752,083	9	194,676	7,188	,000
Error	866,667	32	27,083		
Total	8782100,000	48			
Corrected Total	323297,917	47			

Post Hoc

Kelompok
Homogeneous Subsets
Viskositas

Student-Newman-Keuls^{a,b}

Kelompok	N	Subset			
		1	2	3	4
1,00	12	310,4167	380,4167	466,6667	521,6667
2,00	12				
3,00	12				
4,00	12				
Sig.		1,000	1,000	1,000	1,000

Waktu
Homogeneous Subsets
Viskositas

Student-Newman-Keuls^{a,b}

Waktu	N	Subset			
		1	2	3	4
1,00	12	401,2500	416,6667	425,8333	435,4167
2,00	12				
3,00	12				
4,00	12				
Sig.		1,000	1,000	1,000	1,000

Lampiran 6. Hasil uji pH sediaan gel piroxicam

Data uji ph				
	F1	F2	F3	F4
Hari 1	6,45	6,24	6,18	6,29
	6,44	6,23	6,17	6,29
	6,45	6,23	6,18	6,28
Hari 7	6,43	6,22	6,17	6,27
	6,43	6,2	6,17	6,28
	6,42	6,22	6,16	6,28
Hari 14	6,42	6,2	6,15	6,27
	6,42	6,21	6,16	6,27
	6,41	6,2	6,15	6,26
Hari 21	6,41	6,19	6,15	6,25
	6,4	6,19	6,14	6,25
	6,4	6,18	6,15	6,26

Lampiran 7. Hasil uji statistik pH sediaan gel piroxicam

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
PH	48	6,2660	,10105	6,14	6,45

One-Sample Kolmogorov-Smirnov Test

		PH
N		48
Normal Parameters ^{a,b}	Mean	6,2660
	Std. Deviation	,10105
	Absolute	,158
Most Extreme Differences	Positive	,156
	Negative	-,158
Kolmogorov-Smirnov Z		1,091
Asymp. Sig. (2-tailed)		,185

Levene's Test of Equality of Error Variances^a

Dependent Variable: PH

F	df1	df2	Sig.
,842	15	32	,628

Tests of Between-Subjects Effects

Dependent Variable: PH

Source	Type III Sum of Squares	df	Mean Square	F	Sig.
Corrected Model	,479 ^a	15	,032	806,200	,000
Intercept	1884,637	1	1884,637	47611891,000	,000
Kelompok	,469	3	,156	3947,842	,000
Waktu	,010	3	,003	80,333	,000
Kelompok * Waktu	,000	9	3,727E-005	,942	,504
Error	,001	32	3,958E-005		
Total	1885,117	48			
Corrected Total	,480	47			

a. R Squared = ,997 (Adjusted R Squared = ,996)

Post Hoc Tests

Kelompok
Homogeneous Subsets
PH

Student-Newman-Keuls^{a,b}

Kelompok	N	Subset			
		1	2	3	4
Formula 3	12	6,1608	6,2092	6,2708	6,4233
Formula 2	12				
Formula 4	12				
Formula 1	12				
Sig.		1,000	1,000	1,000	1,000

Waktu

Homogeneous Subsets
PH

Student-Newman-Keuls^{a,b}

Waktu	N	Subset			
		1	2	3	4
Hari ke 21	12	6,2475	6,2600	6,2708	6,2858
Hari ke 14	12				
Hari ke 7	12				
Hari ke 1	12				
Sig.		1,000	1,000	1,000	1,000

Lampiran 8. Hasil uji daya sebar gel piroxicam

Data daya sebar (cm)					
		Hari 1	Hari 7	Hari 14	Hari 21
F1	Beban 50	2,9	2,8	2,7	2,7
		2,8	2,7	2,6	2,8
		2,8	2,8	2,6	2,7
	Beban 100	3,2	3,2	2,9	2,8
		3,1	3,3	2,9	2,7
		3,1	3,4	2,8	3,1
	Beban 150	3,6	3,8	3,4	3,4
		3,7	3,9	3,6	3,5
		3,7	3,7	3,6	3,4
F2	Beban 50	2,9	2,7	2,7	2,5
		2,8	2,8	2,6	2,6
		2,9	2,7	2,7	2,6
	Beban 100	3,2	3	2,7	2,4
		3,3	3	2,7	2,6
		3,3	2,7	2,5	2,7
	Beban 150	3,6	3,3	3,1	2,9
		3,8	3,3	3	2,8
		3,9	3	2,7	2,8
F3	Beban 50	2,1	2,4	2,1	1,9
		2,1	2,5	1,9	1,9
		2,4	2,5	2	1,8
	Beban 100	2,2	2,3	2,3	2,3
		2,4	2,4	2,3	2,4
		2,5	2,4	2,4	2,4
	Beban 150	2,6	2,8	2,6	2,6
		2,7	2,7	2,6	2,7
		2,7	2,7	2,7	2,6
F4	Beban 50	2,4	2,2	1,6	1,9
		2,3	2,2	1,6	1,8
		2,3	2,1	1,7	1,8
	Beban 100	2,1	2,1	1,8	1,6
		2,2	2	1,8	1,5
		2,2	2	1,9	1,6
	Beban 150	2,3	2,2	2	1,9
		2,2	2,1	1,9	2,2
		2,3	2,2	2	1,8

Lampiran 9. Hasil uji statistik daya sebar gel piroxicam

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Dayasebar	144	2,6063	,54545	1,60	3,90

One-Sample Kolmogorov-Smirnov Test

		Dayasebar
N		144
Normal Parameters ^{a,b}	Mean	2,6063
	Std. Deviation	,54545
	Absolute	,111
Most Extreme Differences	Positive	,111
	Negative	-,068
Kolmogorov-Smirnov Z		1,335
Asymp. Sig. (2-tailed)		,057

Levene's Test of Equality of Error Variances^a

Dependent Variable: Dayasebar

F	df1	df2	Sig.
4,097	15	128	,000

Post Hoc Tests

Kelompok Homogeneous Subsets

Dayasebar

Student-Newman-Keuls^{a,b}

Kelompok	N	Subset			
		1	2	3	4
Formula 4	36	1,9972	2,3889	2,9056	3,1333
Formula 3	36				
Formula 2	36				
Formula 1	36				
Sig.		1,000	1,000	1,000	1,000

Waktu
Homogeneous Subsets

Dayasebar

Student-Newman-Keuls^{a,b}

Waktu	N	Subset	
		1	2
Hari ke 21	36	2,4389	
Hari ke 14	36	2,4806	
Hari ke 7	36		2,7222
Hari ke 1	36		2,7833
Sig.		,530	,357

Lampiran 10. Hasil uji daya lekat sediaan gel piroxicam

Data uji daya lekat (detik)				
	F1	F2	F3	F4
Hari 1	2,12	2,18	4,12	4,58
	2,25	2,05	4,08	4,5
	2,19	2,13	4,13	5,01
Hari 7	2,09	2,32	4,15	4,6
	2,21	2,46	4,11	4,89
	2,1	2,54	4,03	5
Hari 14	2,45	2,58	4,38	5,03
	2,37	2,49	4,3	5,1
	2,28	3,01	4,23	4,58
Hari 21	3,09	3,11	4,3	5,36
	3,02	3,23	4,37	5,2
	2,56	3,28	4,24	5,42

Lampiran 11. Hasil uji statistik daya lekat sediaan gel piroxicam

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Dayalekat	48	3,4731	1,17883	1,00	5,42

One-Sample Kolmogorov-Smirnov Test

		Dayalekat
N		48
Normal Parameters ^{a,b}	Mean	3,4731
	Std. Deviation	1,17883
	Absolute	,171
Most Extreme Differences	Positive	,171
	Negative	-,161
Kolmogorov-Smirnov Z		1,188
Asymp. Sig. (2-tailed)		,119

Levene's Test of Equality of Error Variances^a

Dependent Variable: Dayalekat

F	df1	df2	Sig.
12,125	15	32	,000

Tests of Between-Subjects Effects

Dependent Variable: Dayalekat

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	58,097 ^a	15	3,873	17,177	,000
Intercept	579,005	1	579,005	2567,838	,000
Kelompok	51,260	3	17,087	75,778	,000
Waktu	4,615	3	1,538	6,823	,001
Kelompok * Waktu	2,222	9	,247	1,095	,394
Error	7,215	32	,225		
Total	644,317	48			
Corrected Total	65,313	47			

Post Hoc Tests

Kelompok Homogeneous Subsets

Dayalekat

Student-Newman-Keuls^{a,b}

Kelompok	N	Subset		
		1	2	3
Formula 1	12	2,3942		
Formula 2	12	2,6150		
Formula 3	12		3,9442	
Formula 4	12			4,9392
Sig.		,263	1,000	1,000

Waktu

Homogeneous Subsets

Dayalekat

Student-Newman-Keuls^{a,b}

Waktu	N	Subset	
		1	2
Hari ke 7	12	3,1158	
Hari 1	12	3,2783	
Hari ke 14	12	3,5667	3,5667
Hari ke 21	12		3,9317
Sig.		,067	,069

Lampiran 12. Hasil uji stabilitas pH sediaan gel piroxicam

Data uji stabilitas pH				
	F1	F2	F3	F4
Hari 1	6,42	6,23	6,18	6,25
	6,43	6,22	6,19	6,24
	6,43	6,22	6,17	6,25
Hari 21	6,4	6,19	6,15	6,2
	6,39	6,2	6,14	6,19
	6,39	6,19	6,13	6,2

Lampiran 13. Hasil uji statistik stabilitas pH sediaan gel piroxicam

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
PH	24	6,2500	,09943	6,13	6,43

One-Sample Kolmogorov-Smirnov Test

		PH
N		24
Normal Parameters ^{a,b}	Mean	6,2500
	Std. Deviation	,09943
	Absolute	,250
Most Extreme Differences	Positive	,250
	Negative	-,170
Kolmogorov-Smirnov Z		1,225
Asymp. Sig. (2-tailed)		,100

Levene's Test of Equality of Error Variances^a

Dependent Variable: PH

F	df1	df2	Sig.
,286	7	16	,950

Tests of Between-Subjects Effects

Dependent Variable: PH

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	,227 ^a	7	,032	647,429	,000
Intercept	937,500	1	937,500	18750000,000	,000
Kelompok	,217	3	,072	1449,556	,000
Waktu	,009	1	,009	176,333	,000
Kelompok * Waktu	,000	3	,000	2,333	,113
Error	,001	16	5,000E-005		
Total	937,727	24			
Corrected Total	,227	23			

Post Hoc Tests

Kelompok
Homogeneous Subset
PH

Student-Newman-Keuls^{a,b}

Kelompok	N	Subset			
		1	2	3	4
Formula 3	6	6,1600			
Formula 2	6		6,2083		
Formula 4	6			6,2217	
Formula 1	6				6,4100
Sig.		1,000	1,000	1,000	1,000

Lampiran 14. Hasil uji stabilitas viskositas sediaan gel piroxicam

Data uji stabilitas viskositas (dPAS)				
	F1	F2	F3	F4
Hari 1	280	300	425	480
	270	310	420	470
	280	300	425	470
Hari 21	285	305	430	485
	290	310	435	480
	295	320	430	475

Lampiran 15. Hasil uji statistik stabilitas viskositas sediaan gel piroxicam

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Viskositas	24	352,0833	88,64826	240,00	480,00

One-Sample Kolmogorov-Smirnov Test

		Viskositas
N		24
Normal Parameters ^{a,b}	Mean	352,0833
	Std. Deviation	88,64826
	Absolute	,183
Most Extreme Differences	Positive	,183
	Negative	-,166
Kolmogorov-Smirnov Z		,894
Asymp. Sig. (2-tailed)		,401

Levene's Test of Equality of Error Variances^a

Dependent Variable: Viskositas

F	df1	df2	Sig.
,600	7	16	,748

Tests of Between-Subjects Effects

Dependent Variable: Viskositas

Source	Type III Sum of Squares	Df	Mean Square	F	Sig.
Corrected Model	180129,167 ^a	7	25732,738	667,660	,000
Intercept	2975104,167	1	2975104,167	77191,892	,000
Kelompok	172545,833	3	57515,278	1492,288	,000
Waktu	7004,167	1	7004,167	181,730	,000
Kelompok * Waktu	579,167	3	193,056	5,009	,012
Error	616,667	16	38,542		
Total	3155850,000	24			
Corrected Total	180745,833	23			

Post Hoc Tests

Kelompok

Homogeneous Subsets

Viskositas

Student-Newman-Keuls^{a,b}

Kelompok	N	Subset			
		1	2	3	4
Formula 1	6	260,0000			
Formula 2	6		278,3333		
Formula 3	6			411,6667	
Formula 4	6				458,3333
Sig.		1,000	1,000	1,000	1,000

Lampiran 16. Data berat badan dan gula darah Kelinci *New Zealand*

No Kelinci	Berat Badan Kelinci	Gula Darah Awal	Gula Darah hari ke-0	Gula Darah hari ke-6	Gula Darah kelinci sembuh
1 (Tidak Diabetes)	2,7 kilogram	82 mg/dL	105 mg/dL	118 mg/dL	108 mg/dL
2 (Diabetes)	3 kilogram	83 mg/dL	257 mg/dL	244 mg/dL	228 mg/dL
3 (Diabetes)	2,9 kilogram	73 mg/dL	250 mg/dL	242 mg/dL	223 mg/dL
4 (Diabetes)	2,8 kilogram	83 mg/dL	254 mg/dL	242 mg/dL	232 mg/dL
5 (Diabetes)	2,9 kilogram	85 mg/dL	251 mg/dL	240 mg/dL	218 mg/dL
6(Diabetes)	2,8 kilogram	87 mg/dL	253 mg/dL	241 mg/dL	235 mg/dL

Lampiran 17. Data perhitungan dosis aloksan

Diketahui :

berat badan standar kelinci : 1,5 kg

Dosis : 150 mg/kgBB

$$\text{Aloksan } 1\% = \frac{1 \text{ gram}}{100 \text{ ml}} = 10 \text{ mg/ml}$$

a. Perhitungan kelinci 1

$$\frac{2,8 \text{ kg}}{1,5 \text{ kg}} \times 150 \text{ mg/kgBB} = 280 \text{ mg}$$

$$\text{Volume pemberian} = \frac{280 \text{ mg}}{10 \text{ mg}} \times 1 \text{ ml} = 28 \text{ ml}$$

Karena volume pemberian terlalu besar, maka volumenya dipekatkan menjadi 5 ml, sehingga konsentrasi aloksan yang digunakan yaitu

$$V_1 \times C_1 = V_2 \times C_2$$

$$5 \text{ ml} \times C_1 = 28 \text{ ml} \times 280 \text{ mg}$$

$$C_1 = 1568 \text{ mg}$$

b. Perhitungan kelinci 2

$$\frac{3 \text{ kg}}{1,5 \text{ kg}} \times 150 \text{ mg/kgBB} = 300 \text{ mg}$$

$$\text{Volume pemberian} = \frac{300 \text{ mg}}{10 \text{ mg}} \times 1 \text{ ml} = 30 \text{ ml}$$

Karena volume pemberian terlalu besar, maka volumenya dipekatkan menjadi 5 ml, sehingga konsentrasi aloksan yang digunakan yaitu

$$V_1 \times C_1 = V_2 \times C_2$$

$$5 \text{ ml} \times C_1 = 30 \text{ ml} \times 300 \text{ mg}$$

$$C_1 = 1800 \text{ mg}$$

c. Perhitungan kelinci 3

$$\frac{2,9 \text{ kg}}{1,5 \text{ kg}} \times 150 \text{ mg/kgBB} = 290 \text{ mg}$$

$$\text{Volume pemberian} = \frac{290 \text{ mg}}{10 \text{ mg}} \times 1 \text{ ml} = 29 \text{ ml}$$

Karena volume pemberian terlalu besar, maka volumenya dipekatkan menjadi 5 ml, sehingga konsentrasi aloksan yang digunakan yaitu

$$V1 \times C1 = V2 \times C2$$

$$5 \text{ ml} \times C1 = 29 \text{ ml} \times 290 \text{ mg}$$

$$C1 = 1682 \text{ mg}$$

d. Perhitungan kelinci 4

$$\frac{2,8 \text{ kg}}{1,5 \text{ kg}} \times 150 \text{ mg/kgBB} = 280 \text{ mg}$$

$$\text{Volume pemberian} = \frac{280 \text{ mg}}{10 \text{ mg}} \times 1 \text{ ml} = 28 \text{ ml}$$

Karena volume pemberian terlalu besar, maka volumenya dipekatkan menjadi 5 ml, sehingga konsentrasi aloksan yang digunakan yaitu

$$V1 \times C1 = V2 \times C2$$

$$5 \text{ ml} \times C1 = 28 \text{ ml} \times 280 \text{ mg}$$

$$C1 = 1,568 \text{ mg}$$

e. Perhitungan kelinci 5

$$\frac{2,9 \text{ kg}}{1,5 \text{ kg}} \times 150 \text{ mg/kgBB} = 290 \text{ mg}$$

$$\text{Volume pemberian} = \frac{290 \text{ mg}}{10 \text{ mg}} \times 1 \text{ ml} = 29 \text{ ml}$$

Karena volume pemberian terlalu besar, maka volumenya dipekatkan menjadi 5 ml, sehingga konsentrasi aloksan yang digunakan yaitu

$$V1 \times C1 = V2 \times C2$$

$$5 \text{ ml} \times C1 = 29 \text{ ml} \times 290 \text{ mg}$$

$$C1 = 1682 \text{ mg}$$

Lampiran 18. Gambar aktivitas penyembuhan luka sayat

Hari ke-1.

uji aktivitas penyembuhan luka





Hari ke-6.

uji aktivitas penyembuhan luka





Hari ke-13.

uji aktivitas penyembuhan luka





Lampiran 19. Hasil uji aktivitas penyembuhan luka sayat**Hasil Uji Aktivitas Penutupan Luka Kelinci****A. Kelinci 1 (tidak diabetes)**

Hari ke-	Tanggal	Penutupan luka (cm)					
		K. Sakit	K(-)/F1	F2	F3	F4	K(+)
0	20 August	2	2,1	2,2	2	2	2,1
1	21 August	1,9	1,8	1,6	1,7	1,8	1,6
2	22 August	1,8	1,8	1,4	1,6	1,7	1,5
3	23 August	1,6	1,6	1,3	1,6	1,5	1,3
4	24 August	1,4	1,5	1	1,3	1,4	1
5	25 August	1,3	1,3	0,9	1	1,1	0,8
6	26 August	1,2	1,3	0,7	0,8	0,9	0,6
7	27 August	1,2	1	0,5	0,7	0,8	0,5
8	28 August	1,1	0,9	0,4	0,4	0,5	0,2
9	29 August	1	0,9	1,8	1,8	0,4	0
10	30 August	0,6	0,5	0	0	0	0
11	31 August	0,3	0	0	0	0	0
12	1 Sept	0	0	0	0	0	0

B. Kelinci 2 (diabetes)

Hari ke-	Tanggal	Penutupan luka (cm)					
		K. Sakit	K(-)/F1	F2	F3	F4	K(+)
0	20 August	2,2	2,3	2,2	2,2	1,9	2,2
1	21 August	2,1	2,1	1,9	2	1,8	1,9
2	22 August	1,9	1,8	1,6	1,9	1,6	1,7
3	23 August	1,7	1,6	1,4	1,6	1,6	1,5
4	24 August	1,5	1,4	1,3	1,5	1,4	1,4
5	25 August	1,5	1,3	1,1	1,5	1,3	1,3
6	26 August	1,2	1,3	0,7	1,1	1,1	1,1
7	27 August	0,8	0,8	0,6	0,9	0,9	0,9
8	28 August	0,7	0,4	0,3	0,6	0,7	0,4
9	29 August	0,4	0,3	0,1	0,5	0,5	0
10	30 August	0,2	0,3	0	0,3	0,3	0
11	31 August	0	0	0	0	0	0

C. Kelinci 3 (diabetes)

Hari ke-	Tanggal	Penutupan luka (cm)					
		K. Sakit	K(-)/F1	F2	F3	F4	K(+)
0	20 August	2,3	2,2	2	2,1	2,1	1,9
1	21 August	2,2	2,1	1,9	2	2	1,8
2	22 August	2,2	1,8	1,8	1,9	1,7	1,8
3	23 August	2	1,5	1,7	1,7	1,7	1,7
4	24 August	1,8	1,5	1,5	1,6	1,6	1,6
5	25 August	1,6	1,3	1,4	1,6	1,5	1,5
6	26 August	1,6	1,2	1,1	1,4	1,3	1,2
7	27 August	1,4	1	1	1	1,1	1,2
8	28 August	1,3	0,7	1	0,8	0,8	0,9
9	29 August	1,1	0,5	0,8	0,8	0,7	0,5
10	30 August	0,9	0,3	0,6	0,5	0,6	0,4
11	31 August	0,7	0,3	0,2	0,3	0,3	0
12	1 Sept	0,5	0	0	0	0	0
13	2 Sept	0	0	0	0	0	0

D. Kelinci 4 (diabetes)

Hari ke-	Tanggal	Penutupan luka (cm)					
		K. Sakit	K(-)/F1	F2	F3	F4	K(+)
0	20 August	2,1	1,9	2	2,4	2,2	2
1	21 August	2	1,8	1,8	2	2,1	1,9
2	22 August	1,8	1,6	1,7	1,9	2	1,7
3	23 August	1,8	1,6	1,6	1,7	2	1,5
4	24 August	1,6	1,4	1,6	1,5	1,8	1,4
5	25 August	1,3	1,2	1,3	1,4	1,6	1,3
6	26 August	1	1,2	1,2	1,1	1,5	1,2
7	27 August	0,8	0,9	1,1	1	1,3	0,9
8	28 August	0,7	0,9	0,7	0,6	1,1	0,7
9	29 August	0,5	0,6	0,4	0,4	0,8	0,6
10	30 August	0,3	0,5	0,3	0,2	0,6	0,4
11	31 August	0,1	0,2	0,3	0,1	0,4	0
12	1 Sept	0	0	0	0	0	0

E. Kelinci 5 (diabetes)

Hari ke-	Tanggal	Penutupan luka (cm)					
		K. Sakit	K(-)/F1	F2	F3	F4	K(+)
0	20 August	2,3	2,2	2,2	2,2	2,1	2
1	21 August	2,2	2,1	2	2,1	2	1,8
2	22 August	2	2,1	1,8	1,9	1,8	1,5
3	23 August	2	1,9	1,7	1,7	1,6	1,3
4	24 August	1,8	1,6	1,5	1,6	1,5	1,1
5	25 August	1,6	1,5	1,4	1,6	1,4	1,1
6	26 August	1,5	1,2	1,2	1,3	1,2	1
7	27 August	1,3	0,9	1,1	1,1	1,1	0,9
8	28 August	1,2	0,9	0,9	1	1	0,7
9	29 August	0,9	0,8	0,8	0,9	1	0,5
10	30 August	0,7	0,6	0,7	0,6	0,7	0,1
11	31 August	0,5	0,4	0,3	0,4	0,5	0
12	1 Sept	0,3	0,2	0	0	0,2	0
13	2 Sept	0	0	0	0	0	0

F. Kelinci 6 (diabetes)

Hari ke-	Tanggal	Penutupan luka (cm)					
		K. Sakit	K(-)/F1	F2	F3	F4	K(+)
0	20 August	2,3	2	2,1	2,2	1,9	2,1
1	21 August	2,1	1,8	2	2,1	1,7	2
2	22 August	2	1,7	1,8	1,9	1,6	1,8
3	23 August	1,8	1,6	1,7	1,8	1,6	1,7
4	24 August	1,5	1,4	1,5	1,7	1,5	1,5
5	25 August	1,3	1,3	1,4	1,4	1,2	1,4
6	26 August	1	1,1	1,2	1,3	1	1,2
7	27 August	0,8	0,7	1,1	1	0,9	1
8	28 August	0,7	0,5	0,8	0,7	0,6	0,7
9	29 August	0,6	0,3	0,5	0,6	0,3	0,5
10	30 August	0,2	0,1	0,2	0,3	0,1	0
11	31 August	0	0	0	0	0	0

Lampiran 20. Hasil statistik uji aktivitas penyembuhan luka sayat

Hasil Uji Normalitas Sediaan

Tests of Normality

Kelompok	Kolmogorov-Smirnov ^a			Shapiro-Wilk			
	Statistic	df	Sig.	Statistic	df	Sig.	
Persen	Kontrol sakit	,252	6	,200*	,860	6	,188
	Kontrol negatif	,227	6	,200*	,859	6	,187
	Formula uji 2	,238	6	,200*	,944	6	,692
	Formula uji 3	,122	6	,200*	,982	6	,961
	Formula uji 4	,209	6	,200*	,906	6	,411
	Kontrol positif	,180	6	,200*	,975	6	,922

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Hasil Uji Homogenitas

Levene's Test of Equality of Error Variances^a

Dependent Variable: Persen

F	df1	df2	Sig.
1,852	5	30	,133

Tests the null hypothesis that the error variance of the dependent variable is equal across groups.^a

a. Design: Intercept + Kelompok

Hasil Uji One Way ANOVA

Descriptives

Persen

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean	
					Lower Bound	Upper Bound
Kontrol sakit	6	55,3333	4,88535	1,99444	50,2065	60,4602
Kontrol negative	6	57,5000	4,13521	1,68819	53,1604	61,8396
Formula uji 2	6	85,8333	4,62241	1,88709	80,9824	90,6843
Formula uji 3	6	78,5000	1,87083	,76376	76,5367	80,4633
Formula uji 4	6	80,3683	2,48637	1,01505	77,7591	82,9776
Kontrol positif	6	90,6667	5,92171	2,41753	84,4522	96,8811
Total	36	74,7003	14,25642	2,37607	69,8766	79,5240

Descriptives

Persen

	Minimum	Maximum
Kontrol sakit	50,00	61,00
Kontrol negative	51,00	61,00
Formula uji 2	79,00	92,00
Formula uji 3	76,00	81,00
Formula uji 4	78,00	84,21
Kontrol positif	83,00	100,00
Total	50,00	100,00

Test of Homogeneity of Variances

Persen

Levene Statistic	df1	df2	Sig.
1,852	5	30	,133

ANOVA

Persen

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	6578,180	5	1315,636	73,717	,000
Within Groups	535,410	30	17,847		
Total	7113,590	35			

Pos Hoc SNK

PersenStudent-Newman-Keuls^a

Kelompok	N	Subset for alpha = 0.05		
		1	2	3
Kontrol sakit	6	55,3333		
Kontrol negative	6	57,5000		
Formula uji 3	6		78,5000	
Formula uji 4	6		80,3683	
Formula uji 2	6			85,8333
Kontrol positif	6			90,6667
Sig.		,381	,450	,057

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 6,000.